News - Teva Pharmaceutical Industries


Popular Filters

101 to 125 of 193 results

US FDA approves Teva's oral contraceptive Quartette


There was good news for Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) when the US Food…

North AmericaPharmaceuticalQuartetteRegulationReproductiveTeva Pharmaceutical IndustriesWomen's Health

ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant


Among the highlights of the annual meeting of the American Academy of Neurology taking place in San Diego,…

AzilectBiotie TherapiesGilenyaLundbeckNeurologicalNovartisODM-101Orion CorpPharmaceuticalResearchTeva Pharmaceutical Industriestozadenant

Ben-Gurion University researchers and Teva develop psoriasis drug


Researchers at Ben-Gurion University of the Negev (BGU), in collaboration with Israel largest drugmaker…

DermatologicalsImmunologicalsPharmaceuticalResearchTeva Pharmaceutical Industries

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Mundipharma's bendamustine plus rituximab doubles PFS in non-Hodgkin lymphoma and MCL patients


Results from the StiL NHL-1 study published in the Lancet today (February 20) show that a first-line…

bendamustineLevactMundipharmaOncologyPharmaceuticalResearchTeva Pharmaceutical IndustriesTreanda

Gilead and Teva settle Viread patent litigation


US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages


US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR


US generics drug major Actavis (NYSE: ACT) has reached a settlement with Mallinckrodt (NYSE: MKG) on…

ActavisAdderall XRExalgoGenericsMallinckrodtNeurologicalNorth AmericaPatentsRegulationShireTeva Pharmaceutical Industries

Teva Pharma's 4th-qtr financials just misses forecasts


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) reported results for the fourth quarter 2012,…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Teva pulls out of CureTech deal; AC Immune drops CI-91


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

News briefs: US Crestor patent upheld; Pfizer animal health plans; Teva South Korea JV


Anglo-Swedish drug major AstraZeneca (LSE: AZ) said on Friday that the US Court of Appeals for the Federal…

Asia-PacificAstraZenecaCrestorGenericsHandok PharmaceuticalsLegalMergers & AcquisitionsNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesZoetis

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million


Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Galena Biopharma leaps on deal with Teva for NeuVax in Israel


Shares of US biotech firm Galena Biopharma (Nasdaq: GALE) leapt 13.7% to $2.32 in pre-market trading…

BiotechnologyGalena BioPharmaLicensingnelipepimut-SNeuVaxOncologyRest of the WorldTeva Pharmaceutical IndustriesVaccines

M&A briefs: BioCryst/Presidio; Pfizer/Nestle; Teva


Shares of USA-based BioCryst Pharmaceuticals (Nasdaq: BCRX) saw its shares rocket as much as 80%, before…

BioCryst PharmaceuticalsFinancialHomeMergers & AcquisitionsNestlePfizerPresidio PharmaceuticalsTeva Pharmaceutical Industries

Teva to raise stake in Rexahn; Pfizer completes NextWave deal


US clinical-stage biopharma company focused on oncology and central nervous system (CNS) therapeutics…

Mergers & AcquisitionsNeurologicalNextWave PharmaceuticalsNorth AmericaOncologyPfizerPharmaceuticalQuillivantResearchRexahn PharmaceuticalsRX-3117Teva Pharmaceutical Industries

XTL Biopharma buys Teva's stake in Proteologics


In a second M&A deal this year, Israel's XTL Biopharmaceuticals (TASE: XTL) announced that it has acquired…

Mergers & AcquisitionsPharmaceuticalProteologicsTeva Pharmaceutical IndustriesXTL Biopharmaceuticals

Novogen to acquire Triaxial Pharma for $1.8 million; EU approves Teva/P&G deal


Biotechnology firm Novogen (ASX: NRT) yesterday announced that it has signed a term sheet in relation…

BiotechnologyMergers & AcquisitionsNovogenPharmaceuticalProcter & GambleRegulationTeva Pharmaceutical IndustriesTriaxial Pharmaceuticals

Canada's Supreme Court paves way for generic Viagra


There was disappointing news for global pharma behemoth Pfizer (NYSE: PFE) yesterday, when the Canadian…

GenericsLegalMen's HealthNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesViagra

Two senior management appointments at Teva


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) yesterday announced two management changes…

GenericsManagementTeva Pharmaceutical Industries

Teva Pharma's earnings beat forecasts, but sales lower than expected


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic drugs maker…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

FDA approves Teva's Synribo for CML; Novartis plans for Tasigna switch


The US Food and Drug Administration on Friday approved Israel-headquartered Teva Pharmaceutical Industries'…

GleevecNorth AmericaNovartisOncologyPatentsPharmaceuticalRegulationResearchSynriboTasignaTeva Pharmaceutical Industries

Teva/Impax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds


Following a review of new data, the US Food and Drug Administration says these indicate that Budeprion…

Bupropion HclGenericsGlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaRegulationTeva Pharmaceutical IndustriesWellbutrin XL

101 to 125 of 193 results

Back to top